Education
About Us
Working with TipRanks
Follow Us
Metagenomi, Inc. (MGX)
NASDAQ:MGX
MGX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$1.23 - $8.40
Previous CloseN/A
Volume382.73K
Average Volume (3M)413.47K
Market Cap
$65.05M
Enterprise Value-$67.45M
Total Cash (Recent Filing)$0.00
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.99
Next Earnings
May 20, 2025EPS Estimate
-0.61Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.61
Shares Outstanding37,383,472
10 Day Avg. Volume337,260
30 Day Avg. Volume413,473
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.17
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.04
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-1.29
Enterprise Value/Ebitda0.81
Forecast
1Y Price Target
$13.50Price Target Upside675.86% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
---
Metagenomi, Inc. News
PremiumCompany Announcements
Metagenomi, Inc. Reports 2024 Financial Results and Pipeline ProgressPremiumCompany Announcements
Metagenomi Reports 2024 Financial Results and Updates---
Bulls Say, Bears Say
Bulls Say
CollaborationsMetagenomi leverages several collaborations with Ionis and Affini-T, which could be a good source of continued non-dilutive funds as development advances.
Gene Editing TechnologyThe company could be a leader in the gene editing space and the current valuation of MGX is viewed as attractive for its disruptive potential.
Pipeline ProgressMGX has nominated a lead development candidate, MGX-001, for the treatment of hemophilia A.
Bears Say
Clinical Data VariabilityThere is variability from subject to subject in the dataset, with the three NHP subjects experiencing greatly variable levels of FVIII expression outcome.
Regulatory TimelineMGX plans to engage with regulators in 2025, and an IND/CTA for MGX-001 remains on track for 2026.
---
Ownership Overview
9.13% Insiders
4.74% Mutual Funds
0.06% Other Institutional Investors
79.67% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
MGX FAQ
What was Metagenomi, Inc.’s price range in the past 12 months?
Metagenomi, Inc. lowest stock price was $1.23 and its highest was $8.39 in the past 12 months.
What is Metagenomi, Inc.’s market cap?
Metagenomi, Inc.’s market cap is $65.05M.
When is Metagenomi, Inc.’s upcoming earnings report date?
Metagenomi, Inc.’s upcoming earnings report date is May 20, 2025 which is in 23 days.
How were Metagenomi, Inc.’s earnings last quarter?
Metagenomi, Inc. released its earnings results on Mar 17, 2025. The company reported -$0.37 earnings per share for the quarter, beating the consensus estimate of -$0.749 by $0.379.
Is Metagenomi, Inc. overvalued?
According to Wall Street analysts Metagenomi, Inc.’s price is currently Undervalued.
Does Metagenomi, Inc. pay dividends?
Metagenomi, Inc. does not currently pay dividends.
What is Metagenomi, Inc.’s EPS estimate?
Metagenomi, Inc.’s EPS estimate is -0.61.
How many shares outstanding does Metagenomi, Inc. have?
Metagenomi, Inc. has 37,383,472 shares outstanding.
What happened to Metagenomi, Inc.’s price movement after its last earnings report?
Metagenomi, Inc. reported an EPS of -$0.37 in its last earnings report, beating expectations of -$0.749. Following the earnings report the stock price went down -7.979%.
Which hedge fund is a major shareholder of Metagenomi, Inc.?
Currently, no hedge funds are holding shares in MGX
---
Metagenomi, Inc. Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$13.50 (675.86% Upside)
$13.50 (675.86% Upside)
Hedge Fund Trend
Decreased
By 2.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $5.1K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 4.0%
Last 30 Days ▼ 4.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-74.18%
12-Months-Change
Fundamentals
Return on Equity
-34.69%
Trailing 12-Months
Asset Growth
-11.03%
Trailing 12-Months
Company Description
Metagenomi, Inc.
Metagenomi, Inc. (MGX) is a biotechnology company focused on advancing gene editing technologies to transform modern medicine. Leveraging a proprietary platform that harnesses the power of metagenomics, Metagenomi discovers novel CRISPR systems and develops gene editing solutions aimed at treating a wide range of genetic disorders. The company operates at the intersection of biotechnology and healthcare, providing innovative tools for therapeutic development and research.
---
MGX Stock 12 Month Forecast
Average Price Target
$13.50
▲(675.86% Upside)
Technical Analysis
Best Analysts Covering MGX
1 Year
1 Year Success Rate
1/8 ratings generated profit
1 Year Average Return
-40.76%
reiterated a buy rating 25 days ago
Copying Mitchell Kapoor's trades and holding each position for 1 Year would result in 12.50% of your transactions generating a profit, with an average return of -40.76% per trade.
---